Bright Minds Biosciences Inc. (DRUG) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Bright Minds Biosciences Inc. (DRUG) Earnings Overview
As of June 22, 2026, Bright Minds Biosciences Inc. (DRUG) reported trailing twelve-month net income of -$28M, reflecting -173.8% year-over-year growth. The company earned $-2.87 per diluted share over the past four quarters.
Looking at the long-term picture, DRUG's historical earnings data spans multiple years. The company achieved its highest annual net income of -$236,151 in fiscal 2019.
Bright Minds Biosciences Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CMPS (-$179M net income), ATAI (-$663M net income, -16142.0% margin), MNMD (-$238M net income), DRUG has comparable earnings metrics. Compare DRUG vs CMPS →
DRUG Earnings vs Peers
Earnings metrics vs comparable public companies
DRUG Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | -336.5% | -$14M | $-1.78 | - | - |
| 2024 | -$3M | +62.0% | -$3M | $-0.65 | - | - |
| 2023 | -$7M | +50.7% | -$7M | $-1.98 | - | - |
| 2022 | -$15M | -73.0% | -$15M | $-6.15 | - | - |
| 2021 | -$9M | -1700.8% | -$9M | $-4.74 | - | - |
| 2020 | $-480,377 | -103.4% | $-474,926 | $-0.38 | - | - |
| 2019 | $-236,151 | - | $-236,151 | $-0.06 | - | - |
Download Data
Export DRUG earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DRUG — Frequently Asked Questions
Quick answers to the most common questions about buying DRUG stock.
What is DRUG earnings per share (EPS)?
DRUG trailing twelve-month (TTM) diluted EPS is $-2.87, reflecting -173.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Bright Minds Biosciences Inc.'s net income?
Bright Minds Biosciences Inc. (DRUG) trailing twelve-month net income is $-28M as of 2025. Earnings declined -173.8% year-over-year.
Is DRUG profitable?
DRUG is not currently profitable on a TTM basis, reporting a net loss of $-28M. Net margin is N/A. Investors should monitor for a return to profitability.
What is DRUG's earnings growth rate?
DRUG compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are DRUG's profit margins?
Bright Minds Biosciences Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -27.9%.
Is DRUG growing earnings?
DRUG earnings are declining — EPS fell -173.8% year-over-year. TTM net income dropped to $-28M. This contrasts with the 5-year CAGR of N/A.
What was DRUG's best earnings year?
Bright Minds Biosciences Inc.'s highest annual net income on record is $-236151.00, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were DRUG's earnings last quarter?
DRUG's most recent reported quarter was Q2 2026. Net income was $-11M with diluted EPS of $-1.12. For a full breakdown of all quarters, see the quarterly earnings table on this page.